---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?
To: mesothelioma77@gmail.com
[1]Crit Rev Oncol Hematol. 2008 Jun 10;
Tosoni A, Franceschi E, Brandes AA
Brain metastasis occurs in 15-40% of cancer patients and is present in approximately 10-16% of patients with metastatic breast disease. However, little is known about prognostic factors enabling the early identification of breast cancer patients at risk of CNS metastases. Therapy for brain metastases should be based on several parameters, such as the assessment of prognostic variables, the extent of neurological and systemic disease, and its chemo-sensitivity to previously administered chemotherapy treatments. In view of the known close correlation between metastatic and primary tumor chemosensitivity, the type of chemotherapy chosen should depend more on the tumor histology than on the cerebral distribution of the single drug. More recent drugs with a high impact on the clinical outcome of metastatic breast cancer patients, such as taxanes or trastuzumab, play only a limited role in the treatment of brain metastases.
___
Source: http://www.hubmed.org/display.cgi?uids=18550383
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?
To: mesothelioma77@gmail.com
[1]Crit Rev Oncol Hematol. 2008 Jun 10;
Tosoni A, Franceschi E, Brandes AA
Brain metastasis occurs in 15-40% of cancer patients and is present in approximately 10-16% of patients with metastatic breast disease. However, little is known about prognostic factors enabling the early identification of breast cancer patients at risk of CNS metastases. Therapy for brain metastases should be based on several parameters, such as the assessment of prognostic variables, the extent of neurological and systemic disease, and its chemo-sensitivity to previously administered chemotherapy treatments. In view of the known close correlation between metastatic and primary tumor chemosensitivity, the type of chemotherapy chosen should depend more on the tumor histology than on the cerebral distribution of the single drug. More recent drugs with a high impact on the clinical outcome of metastatic breast cancer patients, such as taxanes or trastuzumab, play only a limited role in the treatment of brain metastases.
___
Source: http://www.hubmed.org/display.cgi?uids=18550383
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc